Sports and marfan syndrome: Awareness and early diagnosis can prevent sudden death

Physician and Sportsmedicine

Volumn 29, Issue 5, 2001, Pages 80-93

  Salim, Mubadda A ^a,b   Alpert, Bruce S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ADOLESCENT; ADULT; AORTA ANEURYSM; AORTA DISEASE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ECTOPIA LENTIS; HUMAN; LIGAMENT INJURY; MARFAN SYNDROME; MITRAL VALVE REGURGITATION; REVIEW; SUDDEN DEATH;

EID: 0035020460     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2001.05.786     Document Type: Review

References (34)

1. Marfan syndrome: A silent killer
2. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene
3. The Marfan syndrome
4. Preparticipaion cardiovascular screening for US collegiate student-athletes
5. Aortic root dilatation among young competitive athletes: Echocardiographic screening of 1929 athletes between 15 and 34 years of age
6. Life expectancy and causes of death in the Marfan syndrome
7. Life expectancy in the Marfan syndrome
8. Revised diagnostic criteria for the Marfan Syndrome
9. Tall stature
10. The Marfan syndrome: Joint and skin manifestations are prevalent and correlated
11. The Marfan syndrome
12. The Marfan syndrome in early childhood: Analysis of 15 patients diagnosed at less than 4 years of age
13. Two-dimensional and Doppler echocardiographic and pathologic characteristics of the infantile Marfan syndrome
14. The molecular genetics of Marfan syndrome and the related microfibrillopathies
15. Marfan syndrome: Defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts
16. Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome
17. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival
18. Aortic distensibility in children with the Marfan syndrome
19. The Marfan syndrome: Abnormal aortic elastic properties
20. Arterial hemodynamic indexes in Marfan's syndrome
21. Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effect of atenolol
22. Effect of long term betablockade on aortic root compliance in patients with Marfan syndrome
23. Assessment of ventricular performance after chronic beta-adrenergic blockade in the Marfan syndrome
24. Influence of d-, 1-, and dl-propranolol, and practolol on beta-amino-propionitrileinduced aortic rupture in turkeys
25. Prophylactic use of propranolol in the Marfan syndrome to prevent aortic dissection
26. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome
27. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome
28. Medical management of young patients with the Marfan syndrome
29. Composite graft repair of Marfan aneurysm of the ascending aorta: Results in 100 patients
30. Replacement of the aortic root in patients with Marfan's syndrome
31. Classification of sports
32. Value of exercise Doppler echocardiography in patients with prosthetic or bioprosthetic cardiac valves
33. 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: Congenital heart disease
34. 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 2: Acquired valvular heart disease